PEG300 (Polyethylene glycol 300), a neutral polymer of molecular weight 300, is a water-soluble, low immunogenic and biocompatible polymer formed by repeating units of ethylene glycol^[1][2].

The FDA has approved polyethylene glycol (PEG) for use as a vehicle or base in foods, cosmetics and pharmaceuticals, including injectable, topical, rectal and nasal formulations. PEG shows little toxicity, and is eliminated from the body intact by either the kidneys (for PEGs < 30 kDa) or in the faeces (for PEGs > 20 kDa). PEG lacks immunogenicity, and antibodies to PEG are generated in rabbits only if PEG is combined with highly immunogenic proteins^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. J.Billingham, et al. Adsorption of polyamine, polyacrylic acid and polyethylene glycol on montmorillonite: An in situ study using ATR-FTIR. Volume 14, Issue 1, March 1997, Pages 19-34.

  [2]. Lee CC, et al. Structural basis of polyethylene glycol recognition by antibody. J Biomed Sci. 2020 Jan 7;27(1):12.  [Content Brief]

  [3]. Harris JM, et al. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003 Mar;2(3):214-21.  [Content Brief]

  [4]. Xiaoqin Wang, et al. Injectable silk-polyethylene glycol hydrogels. Acta Biomater. 2015 Jan;12:51-61.  [Content Brief]

  [5]. Ellen Weisberg, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20.  [Content Brief]